Thermo Fisher Scientific Inc. $TMO Shares Sold by Baer Investment Advisory LLC

Baer Investment Advisory LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,488 shares of the medical research company’s stock after selling 125 shares during the period. Thermo Fisher Scientific makes up approximately 2.0% of Baer Investment Advisory LLC’s investment portfolio, making the stock its 21st biggest holding. Baer Investment Advisory LLC’s holdings in Thermo Fisher Scientific were worth $1,414,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Riverwater Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 16.1% during the second quarter. Riverwater Partners LLC now owns 1,927 shares of the medical research company’s stock worth $781,000 after buying an additional 267 shares during the period. Chilton Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 68.0% during the second quarter. Chilton Capital Management LLC now owns 107,024 shares of the medical research company’s stock worth $43,394,000 after buying an additional 43,319 shares during the period. Resonant Capital Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 9.1% during the second quarter. Resonant Capital Advisors LLC now owns 1,575 shares of the medical research company’s stock worth $639,000 after buying an additional 132 shares during the period. New Hampshire Trust lifted its stake in shares of Thermo Fisher Scientific by 0.5% during the second quarter. New Hampshire Trust now owns 6,713 shares of the medical research company’s stock worth $2,722,000 after buying an additional 32 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 5.4% during the second quarter. Oppenheimer Asset Management Inc. now owns 94,160 shares of the medical research company’s stock worth $38,178,000 after buying an additional 4,816 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on TMO shares. JPMorgan Chase & Co. lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Leerink Partners boosted their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Citigroup boosted their target price on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a research report on Thursday. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $595.75.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $573.07 on Monday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $216.40 billion, a PE ratio of 33.11, a price-to-earnings-growth ratio of 3.35 and a beta of 0.77. The stock’s 50-day moving average price is $504.04 and its 200-day moving average price is $453.56.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same period last year, the firm earned $5.28 EPS. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,666 shares of company stock valued at $13,990,971 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.